ALAMEDA, Calif., April 28, 2015 (GLOBE NEWSWIRE) -- Singulex, Inc., the developer and leading provider of Single Molecule Counting technology for clinical diagnostics and scientific discovery, today announced that the Japanese Patent Office has granted a key patent covering methods for detecting or monitoring cardiovascular conditions by measuring the biomarkers cardiac Troponin-I (cTnI) and Interleukin 17-A (IL-17A) in highly sensitive assays. Additionally, the Japanese patent claims one or more of Interleukin-6 (IL-6), Tumor Necrosis Factor-alpha (TNF-a), and various forms of B-type natriuretic peptides in combination with cTnI and IL-17A for detecting and monitoring the cardiovascular conditions.
Japanese Patent No. 5678045, entitled Highly Sensitive Biomarker Panels, provides patent protection in Japan through June 2029, and extends the Company's portfolio of 22 issued patents related to its core SMCTM technology and biomarker assays. Singulex was previously granted United States Patent 8,450,069 that covers methods for assessing cardiovascular health and damage by measuring cTnI, IL-6, and IL-17A, along with one or more of TNF-a and BNP, in platform-independent highly sensitivity assays. This patent provides Singulex exclusive US commercial rights in these assays and methods through June 2030. Similar patents are pending in numerous countries.
Singulex patents include five U.S. patents on the core technology inside the Sgx ClarityTM System, Singulex's second generation scanning system, a fully integrated in vitro diagnostic platform in development at Singulex.
"We are committed to advancing the clinical understanding and use of high sensitivity biomarkers for the management of chronic diseases, and I am pleased with the continued progress of our clinical programs that support our CLIA-licensed laboratory business as well as our emerging in vitro Diagnostics business, all based upon our Single Molecule Counting technology," said Guido Baechler, President and Chief Executive Officer of Singulex. "The granting of this new Japanese patent, and others like it, further validate the unique and proprietary nature of using our highly sensitive biomarker assays to better manage patients affected with severe disease."
Singulex is committed to developing highly sensitive biomarker assays based on clinical evidence and, as of April 2015, 85 published studies involving over 66,000 patients have appeared in peer-reviewed journals demonstrating the significance of ultrasensitive SMC technology for the assessment and management of patients with chronic disease.
About Singulex, Inc.
Singulex is the developer and leading provider of single molecule counting technology for clinical diagnostics and scientific discovery. Singulex's proprietary SMC technology enables physicians and scientists to detect biomarkers of disease that were previously undetectable. Powered by SMC technology, Singulex's ultrasensitive immunoassay solutions and lab testing services are transforming patient care from reactive disease treatment to proactive health management and fueling the discovery and development of new therapeutics.
Singulex provides SMC technology to leading pharmaceutical R&D laboratories, clinical research organizations (CROs) and academic institutions around the world through its Research-Use-Only Erenna® Immunoassay System. The Singulex Clinical Lab Testing Services consist of a CLIA-licensed and CAP-accredited laboratory that currently provides a comprehensive menu of advanced cardiovascular disease testing utilizing SMC technology. Singulex currently is developing the Sgx Clarity System, a fully-automated in vitro diagnostics system that will bring the benefits of its SMC technology to hospital and reference labs worldwide. For further information, please visit www.singulex.com.
CONTACT: Media: Denise Powell Red House Consulting 510.703.9491 email@example.comSource:Singulex, Inc.